Blanket Purchase Agreement 36F79721D0249-36E79721A0024

This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to CSL Behring L.L.C., a global biotherapeutics company that provides specialty pharmaceutical products to the VA. The BPA has a ceiling value of $17,500,000 and allows VA facilities nationwide to efficiently order the medication HAEGARDA, a C1 inhibitor treatment for hereditary angioedema, as needed through September 2025.

The VA Greater Los Angeles Healthcare System (GLA HCS) Pharmacy also issued a BPA call order under CSL Behring's Federal Supply Schedule (FSS) contract for the procurement of HAEGARDA, valued at $87,956.80. This BPA call supports the VA's nationwide healthcare system, as CSL Behring holds a larger $201,482,280 FSS contract for Pharmaceuticals and Drugs (FSS-61-IB) that does not have a set-aside designation. These contract vehicles enable the VA to streamline procurement of critical medications for veterans while maintaining pre-negotiated pricing and terms.